Search Results - "Keystone E"

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors: Keystone E van der Heijde D Mason D Jr. et al.

Source: Arthritis & Rheumatism. Nov2008, Vol. 58 Issue 11, p3319-3329. 11p.

Improvement in Patient-Reported Outcomes in a Rituximab Trial in Patients With Severe Rheumatoid Arthritis Refractory to Anti-Tumor Necrosis Factor Therapy.

Authors: Keystone, E. Burmester, G. R. Fume, R. et al.

Source: Arthritis & Rheumatism. Jun2008, Vol. 58 Issue 6, p785-793. 9p. 5 Charts, 3 Graphs.

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis.

Authors: Keystone E Fleischmann R Emery P et al.

Source: Arthritis & Rheumatism. Dec2007, Vol. 56 Issue 12, p3896-3908. 13p.

Elevation of a γδ T cell subset in peripheral blood and synovial fluid of patients with rheumatoid arthritis.

Authors: Keystone, E. C. Rittershaus, C. Wood, N. et al.

Source: Clinical & Experimental Immunology. Apr1991, Vol. 84 Issue 1, p78-82. 5p.

Impaired autologous mixed lymphocyte reaction (AMLR) reactivity of peripheral blood T cell subsets in rheumatoid arthritis.

Authors: Keystone, E. C. Poplonski, L. Snow, K. M. et al.

Source: Clinical & Experimental Immunology. Nov1989, Vol. 78 Issue 2, p184-188. 5p.

Origin of defective T lymphocyte-suppressor activating factor interaction in patients with rheumatoid arthritis.

Authors: Keystone, E. C. Budz-Tymkfwycz, S. Toewsv, M. et al.

Source: Clinical & Experimental Immunology. Jul1987, Vol. 69 Issue 1, p48-56. 9p.

lmmunoregulatory T cell subpopulations in patients with scleroderma using monoclonal antibodies.

Authors: Keystone, E. C. C. Lau Glamdam, D. D. et al.

Source: Clinical & Experimental Immunology. May1982, Vol. 48 Issue 2, p443-448. 6p.

Role of antibody in the protection of mice from arthritis induced by Mycoplasma pulmonis.

Authors: Keystone, E. C. Cunningham, A.J. Metcalee, A. et al.

Source: Clinical & Experimental Immunology. Feb1982, Vol. 47 Issue 2, p253-259. 7p.

Enhanced resistance of mice to plasma pulmonis-induced arthritis by administration of killed Corynebacterium parvum.

Authors: Keystone, E. C. Taylor-Robinson, D. Ling, L. et al.

Source: Clinical & Experimental Immunology. Nov1981, Vol. 46 Issue 2, p355-362. 8p.

Lymphocyte subpopulations and reactivity to mitogens in patients with scleroderma.

Authors: Baron, M. Keystone, E. C. Gladman, D. D. et al.

Source: Clinical & Experimental Immunology. Oct1981, Vol. 46 Issue 1, p70-76. 7p.

Enhanced delayed hypersensitivity skin test reactivity with serial testing in healthy volunteers.

Authors: Keystone, E. C. Demerieux, P. Gladman, D. et al.

Source: Clinical & Experimental Immunology. Apr1980, Vol. 40 Issue 1, p202-205. 4p.

Impaired antigen-specific suppressor cell activity in patients with systemic lupus erythematosus.

Authors: Gladman, D. Keystone, E. Urowitz, M. et al.

Source: Clinical & Experimental Immunology. Apr1980, Vol. 40 Issue 1, p77-82. 6p.

Is a step-down regimen more effective than a step-up regimen in the treatment of early rheumatoid arthritis?

Authors: Keystone, E. C.¹ ksnow@mtsinai.on.ca

Source: Nature Clinical Practice Rheumatology. Aug2008, Vol. 4 Issue 8, p396-397. 2p.

Prévention des lésions structurales articulaires après un an de traitement par rituximab chez les patients atteints de polyarthrite rhumatoïde avec réponse inadéquate à un ou plusieurs anti-TNF (étude REFLEX)

Authors: Keystone, E. Mariette, X. Emery, P. et al.

Source: Revue du Rhumatisme. Nov2006, Vol. 73 Issue 10/11, p1029-1030. 2p.

O.22 - Baricitinib contre placebo ou adalimumab chez des patients atteints de polyarthrite rhumatoïde (PR) active et présentant une réponse inadéquate au méthotrexate (MTX) : Résultats d’une étude de phase 3 de 52 semaines RA-BEAM

Authors: Taylor, P. Keystone, E. Van Der Heijde, D. et al.

Source: Revue du Rhumatisme. Nov2016 Supplement 1, Vol. 83, pA93-A94. 1p.

Reply.

Authors: Fatima, Safoora Schieir, O. Keystone, E. C. et al.

Source: Arthritis & Rheumatology. Jan2022, Vol. 74 Issue 1, p178-180. 3p.

PMS52 Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Agaisnt Rheumatism: Analysis Based on Patient Reported Outcomes from 3 Phase III Clinical Trials of Golimumab

Authors: Han, C. Keystone, E. Fleischmann, R. et al.

Source: Value in Health. pA43-A43. 1p.

PMS57 ASSOCIATION OF CLINICAL REMISSION AND NORMALIZED PATIENT REPORTED OUTCOMES: A VALIDATION OF TREAT-TO-TARGET FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS USING POOLED DATA FROM 3 PHASE III GOLIMUMAB CLINICAL TRIALS

Authors: Keystone, E. Fleischmann, R. Han, C. et al.

Source: Value in Health. pA133-A133. 1p.

Retraitement par rituximab dans la polyarthrite rhumatoïde: maintien de l'efficacité chez des patients ayant présenté une réponse inadéquate à au moins un anti-TNF

Authors: Keystone, E. Dougados, M. Fleischmann, R.M. et al.

Source: Revue du Rhumatisme. Nov2007, Vol. 74 Issue 10/11, p996-996. 1p.

L'inhibition de la progression radiologique avec le rituximab ne dépend pas de l'efficacité clinique: résultats d'une étude chez des patients atteints de polyarthrite rhumatoïde et présentant une réponse inadéquate à au moins 1 anti-TNF (REFLEX)

Authors: Keystone, E. Mariette, X. Emery, P. et al.

Source: Revue du Rhumatisme. Nov2007, Vol. 74 Issue 10/11, p996-996. 1p.